Kazia Therapeutics Limited - American Depositary Shares (KZIA)
KZIA moved a median of -1.07% 30 minutes after news, and -3.09% by the close. How KZIA actually reacts to news — the realized, point-in-time move the market made, measured across 393 labeled events over the last three years with zero look-ahead.
KZIA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.00% | 36% | 369 |
| 30-min | -1.07% | 34% | 384 |
| 60-min | -0.85% | 36% | 386 |
| to close | -3.09% | 35% | 386 |
| Middle 50% of KZIA reactions | -4.35% to +0.93% |
|---|---|
| Median reaction (30-min) | -1.07% |
| Measured reactions | 393 |
Half of all Kazia Therapeutics Limited - American Depositary Shares news events land between -4.35% and +0.93% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How KZIA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 16 | -2.10% | 13% | -1.34% |
| Rating reiterations | 15 | +2.43% | 67% | -4.10% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how KZIA ranks against every other measured name →
That’s how KZIA usually reacts — get an email when it moves on news →Email me when KZIA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KZIA's baseline. Nothing else.
Recent KZIA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form EFFECT Kazia Therapeutics Limit | SEC filing · Form EFFECT | SEC EDGAR | -1.06% | +1.70% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Sep 22 | SEC filing · Form 6-K | SEC EDGAR | +0.33% | +1.11% | |
| Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders | Press release | PR Newswire | +0.33% | +1.11% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Sep 18 | SEC filing · Form 6-K | SEC EDGAR | +2.37% | +1.14% | |
| Hummingbird Bioscience Appoints Dr. James Garner as President | Press release | GlobeNewswire | -0.54% | -6.75% | |
| Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer | Press release | Canada Newswire | -0.24% | -4.96% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Sep 01 | SEC filing · Form 6-K | SEC EDGAR | +0.27% | -0.40% | |
| Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer | Press release | PR Newswire | -6.06% | -7.74% | |
| Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy | Press release | Canada Newswire | -6.06% | -7.74% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Aug 31 | SEC filing · Form 6-K | SEC EDGAR | -0.36% | +0.51% | |
| Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering | Press release | Canada Newswire | -6.06% | -7.74% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Aug 28 | SEC filing · Form 6-K | SEC EDGAR | -1.91% | -12.27% | |
| Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering | Press release | Canada Newswire | -1.91% | -12.27% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Aug 27 | SEC filing · Form 6-K | SEC EDGAR | -1.91% | -12.27% | |
| Kazia Therapeutics Limited Announces Proposed Public Offering | Press release | Canada Newswire | -1.91% | -12.27% | |
| Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer | Press release | Canada Newswire | -1.91% | -12.27% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Jul 28 | SEC filing · Form 6-K | SEC EDGAR | -2.49% | +3.59% | |
| Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer | Press release | GlobeNewswire | -2.49% | +3.59% | |
| High-Grade Glioma Market Witnesses Strong Momentum During the Forecast Period (2026-2036) with Increasing Clinical Activity and Drug Development | DelveInsight | Press release | PR Newswire | +0.00% | -7.21% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Jun 02 | SEC filing · Form 6-K | SEC EDGAR | +1.51% | -3.99% | |
| Kazia Therapeutics Appoints James Levine as Chief Financial Officer | Press release | PR Newswire | +1.51% | -3.99% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: May 26 | SEC filing · Form 6-K | SEC EDGAR | -0.87% | -9.48% | |
| Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer | Press release | PR Newswire | -0.87% | -9.48% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Apr 27 | SEC filing · Form 6-K | SEC EDGAR | -0.81% | -3.24% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Apr 15 | SEC filing · Form 6-K | SEC EDGAR | -14.09% | -9.09% | |
| Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform | Press release | PR Newswire | -14.09% | -9.09% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Apr 13 | SEC filing · Form 6-K | SEC EDGAR | +2.61% | +7.26% | |
| Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform | Press release | PR Newswire | +2.61% | +7.26% | |
| Centri Announces Panel Topics and Featured Programming for Second Annual Capital Conference at Nasdaq on April 14 | Press release | ACCESS Newswire | +0.55% | +0.27% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +2.32% | -2.05% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -2.53% | |
| Form EFFECT KAZIA THERAPEUTICS LTD | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -2.53% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -4.22% | |
| Form F-3 KAZIA THERAPEUTICS LTD | SEC filing · Form F-3 | SEC EDGAR | -6.72% | +0.00% | |
| Centri Announces Participating Companies for Second Annual Capital Conference at Nasdaq | Press release | ACCESS Newswire | — | +1.26% | |
| Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) | Press release | PR Newswire | +1.46% | -5.18% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Jan 27 | SEC filing · Form 6-K | SEC EDGAR | -10.77% | -8.33% | |
| Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer | Press release | PR Newswire | -10.77% | -8.33% | |
| Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End | Press release | PR Newswire | +2.67% | +3.51% | |
| Form EFFECT KAZIA THERAPEUTICS LTD | SEC filing · Form EFFECT | SEC EDGAR | -4.68% | -17.27% | |
| Form EFFECT KAZIA THERAPEUTICS LTD | SEC filing · Form EFFECT | SEC EDGAR | -6.00% | -13.42% | |
| Kazia Therapeutics Regains Full Nasdaq Listing Compliance | Press release | PR Newswire | -0.91% | -9.01% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Dec 19 | SEC filing · Form 6-K | SEC EDGAR | -0.91% | -9.01% | |
| Form F-1 KAZIA THERAPEUTICS LTD | SEC filing · Form F-1 | SEC EDGAR | -0.91% | -9.01% | |
| Form F-1/A KAZIA THERAPEUTICS LTD | SEC filing · Form F-1 | SEC EDGAR | -0.91% | -9.01% | |
| Form POS AM KAZIA THERAPEUTICS LTD | SEC filing · Form POS | SEC EDGAR | -0.91% | -9.01% | |
| Form D KAZIA THERAPEUTICS LTD | SEC filing · Form D | SEC EDGAR | -1.30% | -0.55% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Dec 10 | SEC filing · Form 6-K | SEC EDGAR | -0.65% | +0.15% | |
| Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+ | Press release | PR Newswire | -10.74% | -17.42% | |
| Form 6-K KAZIA THERAPEUTICS LTD For: Dec 05 | SEC filing · Form 6-K | SEC EDGAR | +1.57% | +3.08% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KZIA section they belong to.
Where else KZIA is measured.
KZIA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Axogen, Inc. (AXGN) | 393 | -0.12% | 48% |
| Fulgent Genetics, Inc. (FLGT) | 393 | +0.04% | 51% |
| OHR PHARMACEUTICALS (OHRP) | 393 | 0.00% | 48% |
| ACADIA Pharmaceuticals Inc. (ACAD) | 392 | -0.14% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Kazia Therapeutics Limited - American Depositary Shares's median reaction calculated?
Every labeled KZIA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 393 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 34% of KZIA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KZIA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.